HC Wainwright Reiterates Buy Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)

Barinthus Biotherapeutics (NASDAQ:BRNS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 270.37% from the stock’s current price.

Separately, Alliance Global Partners dropped their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

Barinthus Biotherapeutics Trading Down 8.3 %

NASDAQ:BRNS opened at $1.35 on Friday. The firm has a 50 day moving average of $1.29 and a 200-day moving average of $1.57. Barinthus Biotherapeutics has a 1 year low of $1.11 and a 1 year high of $4.16. The stock has a market capitalization of $53.22 million, a P/E ratio of -0.91 and a beta of -0.59.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.23. The company had revenue of $14.97 million during the quarter. During the same period in the previous year, the firm earned ($0.37) EPS. As a group, analysts forecast that Barinthus Biotherapeutics will post -1.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Several institutional investors have recently modified their holdings of BRNS. M&G Plc acquired a new position in Barinthus Biotherapeutics in the 2nd quarter worth $7,276,000. Alphabet Inc. bought a new position in shares of Barinthus Biotherapeutics during the second quarter worth about $2,119,000. DC Funds LP acquired a new stake in Barinthus Biotherapeutics in the 1st quarter valued at approximately $1,528,000. BlueCrest Capital Management Ltd bought a new stake in Barinthus Biotherapeutics in the 1st quarter valued at approximately $1,292,000. Finally, Ipswich Investment Management Co. Inc. acquired a new position in Barinthus Biotherapeutics during the 2nd quarter worth approximately $32,000. Institutional investors own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.